Genetic Technologies Limited
GNTLF
$0.07
-$6.27-98.90%
| Weiss Ratings | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 6.53 | |||
| Price History | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -93.00% | |||
| 2-Year Total Return | -65.00% | |||
| 3-Year Total Return | -93.64% | |||
| 5-Year Total Return | -86.00% | |||
| 52-Week High % Change | -98.90% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.34 | |||
| 52-Week Low Price | $0.07 | |||
| 52-Week Low Price (Date) | Nov 06, 2023 | |||
| 52-Week High Price (Date) | Aug 21, 2023 | |||
| Valuation | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.38M | |||
| Enterprise Value | 8.23M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.07 | |||
| Earnings Per Share Growth | 15.25% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.19 | |||
| Price/Book (Q) | 2.46 | |||
| Enterprise Value/Revenue (TTM) | 2.05 | |||
| Price | $0.07 | |||
| Enterprise Value/EBITDA (TTM) | -2.13 | |||
| Enterprise Value/EBIT | -2.07 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 115.42M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 61 3 8412 7000 | |||
| Address | 60-66 Hanover Street Fitzroy, VIC 3065 | |||
| Website | genetype.com | |||
| Country | Australia | |||
| Year Founded | 1987 | |||
| Profitability | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -99.35% | |||
| Profit Margin | -123.95% | |||
| Management Effectiveness | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -51.47% | |||
| Return on Equity | -- | |||
| Income Statement | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.65M | |||
| Total Revenue (TTM) | 6.81M | |||
| Revenue Per Share | $0.06 | |||
| Gross Profit (TTM) | 4.19M | |||
| EBITDA (TTM) | -6.55M | |||
| EBIT (TTM) | -6.77M | |||
| Net Income (TTM) | -8.44M | |||
| Net Income Avl. to Common (TTM) | -8.44M | |||
| Total Revenue Growth (Q YOY) | -2.99% | |||
| Earnings Growth (Q YOY) | -16.50% | |||
| EPS Diluted (TTM) | -0.07 | |||
| EPS Diluted Growth (Q YOY) | 6.70% | |||
| Balance Sheet | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.54M | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 3.90M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.28M | |||
| Current Ratio (Q) | 1.670 | |||
| Book Value Per Share (Q) | $0.03 | |||
| Total Assets (Q) | 5.77M | |||
| Total Current Liabilities (Q) | 2.33M | |||
| Total Debt (Q) | 260.60K | |||
| Total Liabilities (Q) | 2.49M | |||
| Total Common Equity (Q) | 3.28M | |||
| Cash Flow | GNTLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 124.80K | |||
| Cash from Financing (TTM) | 4.00M | |||
| Net Change in Cash (TTM) | -796.70K | |||
| Levered Free Cash Flow (TTM) | -3.06M | |||
| Cash from Operations (TTM) | -5.05M | |||
